YZYBIO-B (02496.HK) intends to implement a full circulation plan for its shares listed in Hong Kong.

Gelonghui, May 12, YZYBIO-B (02496.HK) announced that in accordance with the "Guidelines", the Board of Directors reviewed and approved the implementation of full circulation for 68,010,299 domestic shares and unlisted foreign shares held by several shareholders (accounting for approximately 35.08% of the total issued share capital of the company as of the date of this announcement). After obtaining all relevant approvals (including the filing notice from the China Securities Regulatory Commission) and complying with all applicable laws, rules, and regulations, these domestic shares and unlisted foreign shares will be converted into the company's H shares, and the company will apply to the Hong Kong Stock Exchange Limited for the approval of these H shares for listing on the Exchange.

Gelonghui Finance20:05

Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.

① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?

cls.cnMay 9 18:07

YZYBIO-B (02496): Hu Liaoyuan has been appointed as Chief Scientific Officer.

YZYBIO-B (02496) announced that Hu Liaoyuan has been appointed as the Chief Scientific Officer of the company. Hu Liaoyuan will be responsible for...

Zhitong FinanceApr 17 21:36

YZYBIO-B: 2024 ANNUAL REPORT

HKEXApr 16 21:53 · Announcements

In terms of performance, Youzhiyou Biological (02496.HK) reported an annual loss narrowed to 97.599 million yuan and will not distribute dividends.

Youzhiyou Biological – B (02496.HK) announced its annual results for the year ended last December, with a loss narrowed to 97.599 million yuan (RMB), compared to a loss of 0.192 billion yuan in the same period last year; with a loss per share of 0.5 yuan. During the period, revenue was 0.108 billion yuan. No dividend was declared.

AASTOCKSMar 31 12:08

YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 28 22:03 · Announcements